- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06568939
Une étude pour évaluer les événements indésirables et la façon dont le téisotuzumab védotine (ABBV-399) infusé par voie intraveineuse (IV) se déplace dans le corps en monothérapie chez des participants adultes atteints d'un cancer du poumon non épidermoïde non à petites cellules (CPNPC) précédemment traité
Une étude mondiale de phase 2, ouverte, randomisée, portant sur deux schémas thérapeutiques de téisotuzumab védotine chez des sujets atteints d'un cancer du poumon non épidermoïde non à petites cellules à surexpression de c-Met précédemment traité, de type sauvage EGFR, localement avancé/métastatique
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to assess how safe telisotuzumab vedotin is in adult participants with NSCLC. Change in disease activity and adverse events will be assessed.
Telisotuzumab vedotin is an investigational drug being developed for the treatment of NSCLC. Participants will be randomly assigned a treatment of telisotuzumab vedotin in 1 of 3 arms at an 1:1:1 ratio. Each group receives intravenous (IV) infusion of telisotuzumab vedotin at different doses. Approximately 150 adult participants with c-Met overexpressing NSCLC will be enrolled in the study at approximately 80 to 90 sites worldwide.
Participants will receive IV telisotuzumab vedotin at 1 of 3 dose regimens as part of a 3 year study duration.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
Contacts et emplacements
Coordonnées de l'étude
- Nom: ABBVIE CALL CENTER
- Numéro de téléphone: 844-663-3742
- E-mail: abbvieclinicaltrials@abbvie.com
Lieux d'étude
-
-
-
São Paulo, Brésil, 01323-020
- Recrutement
- Hospital Alemao Oswaldo Cruz - Sao Paulo /ID# 272512
-
-
Ceará
-
Fortaleza, Ceará, Brésil, 60810-180
- Recrutement
- Suporte Nutricional e Quimioterapia LTDA - PRONUTRIR /ID# 273203
-
-
Paraná
-
Curitiba, Paraná, Brésil, 80510-130
- Recrutement
- Ictrials Pesquisa E Desenvolvimento /ID# 276681
-
-
Pará
-
Belém, Pará, Brésil, 66063-495
- Recrutement
- Cto - Centro De Tratamento Oncologico /ID# 276699
-
-
Pernambuco
-
Recife, Pernambuco, Brésil, 50040-000
- Recrutement
- Hospital De Cancer De Pernambuco /ID# 276104
-
-
Rio Grande do Norte
-
Natal, Rio Grande do Norte, Brésil, 59075-740
- Recrutement
- Liga Norte Riograndense Contra O Cancer /ID# 273183
-
-
Rio Grande do Sul
-
Ijuí, Rio Grande do Sul, Brésil, 98700-000
- Recrutement
- Oncosite - Centro de Pesquisa Clinica em Oncologia /ID# 272513
-
-
Santa Catarina
-
Florianópolis, Santa Catarina, Brésil, 88020-210
- Recrutement
- Cepen - Centro De Pesquisa E Ensino Em Oncologia De Santa Catarina /ID# 273204
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Chine, 101149
- Recrutement
- Beijing Chest Tumor Hospital /ID# 271935
-
-
Fujian
-
Fuzhou, Fujian, Chine, 350014
- Recrutement
- Fujian Province Cancer Hospital /ID# 276178
-
-
Guangxi
-
Nanning, Guangxi, Chine, 530021
- Recrutement
- Affiliated Cancer Hospital of Guangxi Medical University /ID# 271931
-
-
Heilongjiang
-
Harbin, Heilongjiang, Chine, 150081
- Recrutement
- Harbin Medical University Cancer Hospital /ID# 271665
-
-
Henan
-
Zhengzhou, Henan, Chine, 450008
- Recrutement
- Henan Cancer Hospital /ID# 271927
-
-
Hubei
-
Wuhan, Hubei, Chine, 430022
- Recrutement
- Union Hospital - Tongji Medical College /ID# 271668
-
-
Jiangxi
-
Nanchang, Jiangxi, Chine, 330006
- Recrutement
- The First Affiliated Hospital of Nanchang University /ID# 271666
-
-
Shaanxi
-
Xi'an, Shaanxi, Chine, 710061
- Recrutement
- The First Affiliated Hospital of Xi'an Jiaotong University /ID# 271928
-
-
Shandong
-
Linyi, Shandong, Chine, 276001
- Recrutement
- LinYi Cancer Hospital /ID# 272068
-
-
Xinjiang
-
Ürümqi, Xinjiang, Chine, 830011
- Recrutement
- Cancer Hospital Affliated to Xinjiang Medical University /ID# 271933
-
-
-
-
-
Haifa, Israël, 3109601
- Recrutement
- Rambam Health Care Campus- Haifa /ID# 270078
-
Jerusalem, Israël, 9103102
- Complété
- Shaare Zedek Medical Center /ID# 270095
-
-
Central District
-
Kefar Sava, Central District, Israël, 4428164
- Recrutement
- Meir Medical Center /ID# 270071
-
Petah Tikva, Central District, Israël, 4941492
- Recrutement
- Rabin Medical Center. /ID# 270087
-
-
Tel Aviv
-
Ramat Gan, Tel Aviv, Israël, 5265601
- Recrutement
- The Chaim Sheba Medical Center /ID# 270068
-
-
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japon, 466-8560
- Recrutement
- Nagoya University Hospital /ID# 277010
-
-
Chiba
-
Kashiwa-shi, Chiba, Japon, 277-8577
- Recrutement
- National Cancer Center Hospital East /ID# 277056
-
-
Hokkaido
-
Sapporo, Hokkaido, Japon, 060-8648
- Recrutement
- Hokkaido University Hospital /ID# 277014
-
-
Hyōgo
-
Kobe, Hyōgo, Japon, 650-0046
- Recrutement
- Kobe Minimally Invasive Cancer Center /ID# 277469
-
-
Kanagawa
-
Sagamihara-shi, Kanagawa, Japon, 252-0375
- Recrutement
- Kitasato University Hospital /ID# 277012
-
-
Miyagi
-
Sendai, Miyagi, Japon, 981-0914
- Recrutement
- Sendai Kousei Hospital /ID# 277023
-
-
Miyazaki
-
Miyazaki, Miyazaki, Japon, 889-1692
- Recrutement
- University of Miyazaki Hospital /ID# 277020
-
-
Okayama-ken
-
Kurashiki-shi, Okayama-ken, Japon, 710-8602
- Recrutement
- Kurashiki Central Hospital /ID# 276995
-
-
Shizuoka
-
Fujieda, Shizuoka, Japon, 426-0077
- Recrutement
- Fujieda Municipal General Hospital /ID# 277025
-
-
Wakayama
-
Wakayama, Wakayama, Japon, 641-8510
- Recrutement
- Wakayama Medical University Hospital /ID# 276997
-
-
-
-
Beograd
-
Belgrade, Beograd, Serbie, 11000
- Recrutement
- Institute for Oncology and Radiology of Serbia /ID# 270561
-
Belgrade, Beograd, Serbie, 11080
- Recrutement
- Clinical Hospital Center - Bezanijska Kosa /ID# 270558
-
Belgrade, Beograd, Serbie, 11000
- Recrutement
- University Clinical Center Serbia /ID# 270808
-
Belgrade, Beograd, Serbie, 11000
- Recrutement
- Military Medical Academy /ID# 279873
-
-
Nisavski Okrug
-
Niš, Nisavski Okrug, Serbie, 18300
- Recrutement
- University Clinical Center Nis /ID# 270557
-
-
Sremski Okrug
-
Kamenitz, Sremski Okrug, Serbie, 21208
- Recrutement
- Institute For Pulmonary Diseases Of Vojvodina /ID# 270559
-
-
Sumadijski Okrug
-
Kragujevac, Sumadijski Okrug, Serbie, 34000
- Recrutement
- University Clinical Center Kragujevac /ID# 275773
-
-
-
-
Central Singapore
-
Singapore, Central Singapore, Singapour, 169611
- Recrutement
- National Cancer Centre Singapore /ID# 271499
-
Singapore, Central Singapore, Singapour, 119074
- Recrutement
- National University Hospital /ID# 271700
-
-
-
-
Arizona
-
Chandler, Arizona, États-Unis, 85224
- Recrutement
- Ironwood Cancer and Research Center /ID# 276370
-
-
Arkansas
-
Little Rock, Arkansas, États-Unis, 72205
- Recrutement
- University of Arkansas for Medical Sciences /ID# 272923
-
-
California
-
Los Angeles, California, États-Unis, 90067
- Recrutement
- Valkyrie Clinical Trials /ID# 271322
-
Los Angeles, California, États-Unis, 90025
- Recrutement
- Start Los Angeles /ID# 284999
-
Oxnard, California, États-Unis, 93030
- Recrutement
- FOMAT Medical Research - Clinica mi Salud by Focil Med /ID# 284816
-
-
Connecticut
-
New Haven, Connecticut, États-Unis, 06510
- Complété
- Yale New Haven Hospital /ID# 271584
-
-
Florida
-
Jacksonville, Florida, États-Unis, 32256
- Recrutement
- Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 270899
-
Ocala, Florida, États-Unis, 34474
- Recrutement
- Ocala Oncology Center /ID# 273697
-
Pembroke Pines, Florida, États-Unis, 33028
- Recrutement
- Memorial Hospital West /ID# 270313
-
St. Petersburg, Florida, États-Unis, 33701-4732
- Recrutement
- Comprehensive Hematology Oncology /ID# 270422
-
St. Petersburg, Florida, États-Unis, 33705
- Recrutement
- Florida Cancer Specialists - North /ID# 271995
-
West Palm Beach, Florida, États-Unis, 33401
- Recrutement
- Florida Cancer Specialists - East /ID# 271993
-
-
Georgia
-
Athens, Georgia, États-Unis, 30607
- Recrutement
- University Cancer and Blood Center /ID# 270969
-
Marietta, Georgia, États-Unis, 30060
- Recrutement
- Northwest Georgia Oncology Centers /ID# 275374
-
Savannah, Georgia, États-Unis, 31404
- Complété
- Memorial University Medical Center /ID# 272467
-
-
Hawaii
-
Honolulu, Hawaii, États-Unis, 96819
- Recrutement
- Kaiser Permanente Moanalua Medical Center /ID# 272916
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60607
- Recrutement
- University of Illinois Hospital and Health Sciences System /ID# 275345
-
Niles, Illinois, États-Unis, 60714
- Recrutement
- Illinois Cancer Specialists /ID# 274678
-
Peoria, Illinois, États-Unis, 61637-0001
- Recrutement
- OSF St. Francis Medical Center /ID# 281591
-
Springfield, Illinois, États-Unis, 62702
- Recrutement
- Springfield Clinic - First /ID# 272576
-
-
Nebraska
-
Lincoln, Nebraska, États-Unis, 68506
- Recrutement
- Nebraska Hematology-Oncology /ID# 272970
-
Omaha, Nebraska, États-Unis, 68130
- Recrutement
- Nebraska Cancer Specialists - Omaha - Wright Street /ID# 271527
-
-
Nevada
-
Reno, Nevada, États-Unis, 89502
- Recrutement
- Renown Regional Medical Center /ID# 273535
-
-
New Jersey
-
East Brunswick, New Jersey, États-Unis, 08816-4096
- Recrutement
- Astera Cancer Care /ID# 272359
-
Teaneck, New Jersey, États-Unis, 07666
- Recrutement
- Regional Cancer Care Associates /ID# 270783
-
-
New York
-
The Bronx, New York, États-Unis, 10461
- Recrutement
- Montefiore Medical Center - Einstein Campus /ID# 277169
-
Westbury, New York, États-Unis, 11590
- Recrutement
- Clinical Research Alliance (SMO/Network/Consortium) /ID# 270455
-
-
North Carolina
-
Pinehurst, North Carolina, États-Unis, 28374
- Recrutement
- FirstHealth of the Carolinas- Speciality Center /ID# 272924
-
-
Ohio
-
Perrysburg, Ohio, États-Unis, 43551
- Recrutement
- Mercy Health - Perrysburg Cancer Center /ID# 270536
-
Zanesville, Ohio, États-Unis, 43701
- Recrutement
- Genesis Healthcare System /ID# 273361
-
-
Pennsylvania
-
Sayre, Pennsylvania, États-Unis, 18840
- Recrutement
- Guthrie Robert Packer Hospital /ID# 270316
-
York, Pennsylvania, États-Unis, 17403
- Recrutement
- Cancer Care Associates Of York /ID# 270971
-
-
South Carolina
-
Charleston, South Carolina, États-Unis, 29425
- Recrutement
- Medical University of South Carolina /ID# 273272
-
Greenville, South Carolina, États-Unis, 29607
- Recrutement
- Saint Francis Cancer Center - Greenville /ID# 276368
-
-
Tennessee
-
Nashville, Tennessee, États-Unis, 37203
- Recrutement
- SCRI Oncology Partners /ID# 270162
-
-
Texas
-
Dallas, Texas, États-Unis, 75246
- Recrutement
- Texas Oncology - Dallas - Worth Street /ID# 278947
-
Tyler, Texas, États-Unis, 75702
- Recrutement
- Texas Oncology - Northeast Texas /ID# 272000
-
-
Utah
-
Ogden, Utah, États-Unis, 84405
- Recrutement
- Community Cancer Trials Of Utah /ID# 276598
-
-
Virginia
-
Fairfax, Virginia, États-Unis, 22031
- Recrutement
- Virginia Cancer Specialists - Fairfax /ID# 272004
-
-
Washington
-
Spokane, Washington, États-Unis, 99208
- Recrutement
- Medical Oncology Associates - Spokane /ID# 277172
-
Tacoma, Washington, États-Unis, 98405
- Recrutement
- Northwest Medical Specialties Tacoma /ID# 270534
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Projected life expectancy of at least 12 weeks.
- Must have c-Met overexpressing non-small cell lung cancer (NSCLC) (defined as >= 25% tumor cells with 3+ staining (high [>= 50% 3+]; intermediate [>= 25% - < 50%]) as assessed by a Sponsor designated immunohistochemistry (IHC) laboratory
- Must have histologically or cytologically documented NSCLC that is locally advanced or metastatic.
- Must have a known epidermal growth factor receptor (EGFR) activating mutation status.
- Actionable alterations in genes other than EGFR are permitted.
- Must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
- Must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.
- Must have received no more than 1 line of prior systemic cytotoxic chemotherapy in the locally advanced or metastatic setting, as stated in the protocol.
- Must have progressed on at least 1 line of prior therapy for locally advanced/metastatic NSCLC, as stated in the protocol.
Exclusion Criteria:
- Adenosquamous or neuroendocrine histology, or sarcomatoid features.
- EGFR activating mutations (e.g., EGFR Exon 19 deletions, T790M, Exon 21 L858R, or Exon 20 insertion mutations).
- Received prior c-Met-targeted antibodies, prior telisotuzumab vedotin, or prior antibody-drug conjugates either targeting c-Met or consisting of monomethylauristatin E.
- Received prior docetaxel therapy.
- Metastases to the central nervous system (CNS). Participants with CNS metastases are eligible only after adequate treatment (such as surgery or, radiotherapy, or drug therapy) is provided, as stated on the protocol.
- History of other malignancies except those stated in the protocol.
- History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan, as noted in the protocol.
- Unresolved clinically significant adverse event (AE) >= Grade 2 from prior anticancer therapy, except for alopecia or anemia. Participants with hormone deficiencies caused by prior anticancer therapy who are asymptomatic and on a stable dose of replacement hormone are eligible for study.
- Major surgery within 21 days prior to randomization.
- Clinically significant condition(s) including but not limited to those listed in the protocol.
- Clinically significant liver disease, including hepatitis, current alcohol abuse, or cirrhosis.
- Grade >= 2 edema or lymphedema.
- Grade >= 2 ascites or pleural effusion.
- Grade >= 2 neuropathy.
- Active uncontrolled bacterial or viral infection.
- Active corneal disorder.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Telisotuzumab Vedotin Dose A
Participants will receive telisotuzumab vedotin dose A, as part of the 3 year study duration. |
Intravenous (IV) Infusion
Autres noms:
|
|
Expérimental: Telisotuzumab Vedotin Dose B
Participants will receive telisotuzumab vedotin dose B, as part of the 3 year study duration. |
Intravenous (IV) Infusion
Autres noms:
|
|
Expérimental: Telisotuzumab Vedotin Dose C
Participants will receive telisotuzumab vedotin dose C, as part of the 3 year study duration. |
Intravenous (IV) Infusion
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Percentage of Participants with Treatment-Emergent Adverse Events (AE)s (Any-grade and Grade >= 2)
Délai: Up to Approximately 3 Years
|
An AE is defined as any untoward medical occurrence, inappropriate participant management decision, unintended disease or injury or any untoward clinical signs (including an abnormal laboratory finding) in participants, users or other persons whether or not related to the investigational medical device. |
Up to Approximately 3 Years
|
|
Percentage of Participants with Treatment-Emergent Interstitial Lung Disease (ILD)
Délai: Up to Approximately 3 Years
|
ILD is defined by ILD standardized MedDRA query (SMQ) (broad) per investigator and determined per adjudication (any-grade and Grade >= 2). |
Up to Approximately 3 Years
|
|
Percentage of Participants with Treatment-Emergent Peripheral Neuropathy
Délai: Up to Approximately 3 Years
|
Peripheral neuropathy is defined by peripheral neuropathy SMQ (narrow) (any-grade and Grade >= 2) |
Up to Approximately 3 Years
|
|
Percentage of Participants with Treatment-Emergent Ocular Surface Disorders
Délai: Up to Approximately 3 Years
|
Treatment-emergent ocular surface disorders defined by corneal epitheliopathy company MedDRA query (CMQ) (any-grade and Grade >= 2). |
Up to Approximately 3 Years
|
|
Percentage of Participants with Treatment-Emergent AEs Leading to Study Drug Discontinuation
Délai: Up to Approximately 3 Years
|
An AE is defined as any untoward medical occurrence, inappropriate participant management decision, unintended disease or injury or any untoward clinical signs (including an abnormal laboratory finding) in participants, users or other persons whether or not related to the investigational medical device. |
Up to Approximately 3 Years
|
|
Percentage of Participants with Grade 5 Treatment-Emergent AEs
Délai: Up to Approximately 3 Years
|
An AE is defined as any untoward medical occurrence, inappropriate participant management decision, unintended disease or injury or any untoward clinical signs (including an abnormal laboratory finding) in participants, users or other persons whether or not related to the investigational medical device. |
Up to Approximately 3 Years
|
|
Objective Response (OR) by Blinded Independent Central Review (BICR)
Délai: Up to Approximately 3 Years
|
OR will be defined as achieving confirmed complete response (CR) or confirmed partial response (PR) based on response evaluation criteria in solid tumors (RECIST), version 1.1. |
Up to Approximately 3 Years
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Concentrations of Telisotuzumab Vedotin Conjugate in Serum
Délai: Up to 26 Weeks
|
Concentrations of telisotuzumab vedotin conjugate in serum. |
Up to 26 Weeks
|
|
Concentrations of Monomethylauristatin E (MMAE) Payload in Plasma
Délai: Up to 26 Weeks
|
Concentrations of MMAE payload in plasma. |
Up to 26 Weeks
|
|
Percentage of Participants with Antidrug Antibodies (ADAs) of Telisotuzumab Vedotin
Délai: Up to 26 Weeks
|
Percentage of participants with ADAs of telisotuzumab vedotin. |
Up to 26 Weeks
|
|
Percentage of Participants with Neutralizing Antidrug Antibodies (nADAs) of Telisotuzumab Vedotin
Délai: Up to 26 Weeks
|
Percentage of participants with nADAs of telisotuzumab vedotin. |
Up to 26 Weeks
|
|
Change in Selected items of the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Délai: Cycle 1: Day 1, Day 8, Cycle 2 D1 and D1 of Every Even Cycle Thereafter, Through 3 Years
|
The PRO-CTCAE is a patient-reported outcome measurement system developed to assess symptomatic toxicity in patients participating in cancer clinical trials. PRO-CTCAE includes 124 items representing 78 symptomatic toxicities drawn from the Common Terminology Criteria for Adverse Events (CTCAE). PRO-CTCAE items evaluate the symptom attributes of frequency, severity, interference, amount, presence/absence. All questions employ a 7-day recall period and are scored from 0 to 4 (or 0/1 for absent/present). |
Cycle 1: Day 1, Day 8, Cycle 2 D1 and D1 of Every Even Cycle Thereafter, Through 3 Years
|
|
Change in GP5 item of the Functional Assessment of Cancer Therapy-General (FACT-G)
Délai: Cycle 1: Day 1, Day 8, Cycle 2 D1 and D1 of Every Even Cycle Thereafter, Through 3 Years
|
The GP5 item ("I am bothered by side effects of treatment") of FACT-G is used to assess overall treatment tolerability in patients by assessing the overall side effect impact on participants. |
Cycle 1: Day 1, Day 8, Cycle 2 D1 and D1 of Every Even Cycle Thereafter, Through 3 Years
|
|
Duration of Response (DoR) by BICR
Délai: Up to Approximately 3 Years
|
DoR is defined for confirmed responders as the time from the participants' initial response (CR or PR) to the first occurrence of radiographic progression per RECIST v1.1 or death from any cause. |
Up to Approximately 3 Years
|
|
Progression-Free Survival (PFS) by BICR
Délai: Up to Approximately 3 Years
|
PFS will be defined as the time from randomization to the first occurrence of radiographic progression based on RECIST version 1.1 or death from any cause. |
Up to Approximately 3 Years
|
|
Overall Survival (OS)
Délai: Up to Approximately 3 Years
|
OS will be defined as the time from randomization to death from any cause. |
Up to Approximately 3 Years
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: ABBVIE INC., AbbVie
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- M25-274
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Délai de partage IPD
For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
Critères d'accès au partage IPD
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .